Asset Details
Do you wish to reserve the book?
Case report of acute hepatorenal failure induced by third-line treatment with tislelizumab in a patient with cholangiocarcinoma: was influenza virus the culprit?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Case report of acute hepatorenal failure induced by third-line treatment with tislelizumab in a patient with cholangiocarcinoma: was influenza virus the culprit?
Do you wish to request the book?
Case report of acute hepatorenal failure induced by third-line treatment with tislelizumab in a patient with cholangiocarcinoma: was influenza virus the culprit?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Case report of acute hepatorenal failure induced by third-line treatment with tislelizumab in a patient with cholangiocarcinoma: was influenza virus the culprit?
2025
Overview
A 72-year-old male diagnosed with cholangiocarcinoma was initiated on third-line therapy comprising Tislelizumab and Anlotinib. Within four days of treatment, he developed fulminant hepatic injury concurrent with acute kidney injury. Despite aggressive management with high-dose glucocorticoids, hepatoprotective agents, comprehensive supportive care, and subsequent anti-infective therapy, his clinical status declined rapidly. In view of the grave prognosis and the family's decision to decline intensive interventions such as plasma exchange, the patient ultimately succumbed to multiorgan failure. This case highlights a potential synergistic interaction between concomitant infection (e.g.,influenza virus) and immune checkpoint inhibitor(ICI) therapy, possibly mediated through enhanced antigenic stimulation and loss of immunoregulatory control, culminating in exaggerated immune activation. This mechanism may have profoundly amplified ICI-related toxicity, leading to fatal multiorgan irAEs. Regarding the issue of immune storms, it is challenging for clinical practice to provide favorable outcomes for patients, and we need to remain highly vigilant.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
Acute Kidney Injury - chemically induced
/ Aged
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Anuria
/ Bile Duct Neoplasms - drug therapy
/ Blood
/ Cholangiocarcinoma - complications
/ Cholangiocarcinoma - drug therapy
/ Fever
/ H1N1 influenza A virus (IAV)
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - adverse effects
/ immune-related adverse events
/ Influenza, Human - complications
/ intrahepatic cholangiocarcinoma (ICC)
/ Jaundice
/ Kinases
/ Liver
/ Liver Failure, Acute - chemically induced
/ Male
/ Multiple organ dysfunction syndrome
/ Patients
/ Toxicity
